U.S. patent application number 14/274131 was filed with the patent office on 2014-11-06 for (2r)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof.
This patent application is currently assigned to Proximagen Limited. The applicant listed for this patent is Proximagen Limited. Invention is credited to Magnus Cernerud, Tom Fleck, Claes Lofstrom, Helena Lundstrom, Alf Nygren, Emma Nylen, Alexander Paptchikhine, Margit Pelcman.
Application Number | 20140329826 14/274131 |
Document ID | / |
Family ID | 43448765 |
Filed Date | 2014-11-06 |
United States Patent
Application |
20140329826 |
Kind Code |
A1 |
Fleck; Tom ; et al. |
November 6, 2014 |
(2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS
THEREOF
Abstract
The present invention relates to a process for the preparation
of compounds which are therapeutically active in the central
nervous system. In one aspect, the invention relates to a process
for the preparation of compounds of the general formula (I):
##STR00001## wherein HA is a pharmaceutically acceptable acid and
R.sub.1-R.sub.4 are each independently selected from the group
consisting of hydrogen, halogen, C.sub.1-C.sub.6-alkyl,
C.sub.1-C.sub.6-alkoxy, and
di-C.sub.1-C.sub.6-alkylamino-C.sub.2-C.sub.6-alkoxy. The invention
also relates to the use of said compound to manufacture a
medicament for the treatment of a serotonin-related disorder.
Inventors: |
Fleck; Tom; (Scotts, MI)
; Cernerud; Magnus; (Stockholm, SE) ; Lundstrom;
Helena; (Sundbyberg, SE) ; Lofstrom; Claes;
(Stockholm, SE) ; Pelcman; Margit; (Stockholm,
SE) ; Paptchikhine; Alexander; (Uppsala, SE) ;
Nylen; Emma; (Jarfalla, SE) ; Nygren; Alf;
(Uppsala, SE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Proximagen Limited |
London |
|
GB |
|
|
Assignee: |
Proximagen Limited
London
GB
|
Family ID: |
43448765 |
Appl. No.: |
14/274131 |
Filed: |
May 9, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13768641 |
Feb 15, 2013 |
8835439 |
|
|
14274131 |
|
|
|
|
13234555 |
Sep 16, 2011 |
8410113 |
|
|
13768641 |
|
|
|
|
12817833 |
Jun 17, 2010 |
8030316 |
|
|
13234555 |
|
|
|
|
11359152 |
Feb 22, 2006 |
7820677 |
|
|
12817833 |
|
|
|
|
10464181 |
Jun 18, 2003 |
7129354 |
|
|
11359152 |
|
|
|
|
60416701 |
Oct 7, 2002 |
|
|
|
60406119 |
Aug 26, 2002 |
|
|
|
60390656 |
Jun 21, 2002 |
|
|
|
Current U.S.
Class: |
514/252.11 |
Current CPC
Class: |
A61P 3/10 20180101; C07D
401/12 20130101; A61P 25/00 20180101; C07D 401/14 20130101; A61P
3/04 20180101 |
Class at
Publication: |
514/252.11 |
International
Class: |
C07D 401/14 20060101
C07D401/14 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 19, 2002 |
SE |
0201881-0 |
Jun 28, 2002 |
SE |
0202041-0 |
Aug 26, 2002 |
SE |
0202516-1 |
Claims
1-34. (canceled)
35. A method for treating or preventing a serotonin-related
disorder in a mammal comprising administering to the mammal a
therapeutically effective amount of a pharmaceutical composition
comprising a compound of formula (I): ##STR00012## wherein
R.sub.1-R.sub.4 are hydrogen and HA is L-malic acid; and a
pharmaceutically acceptable carrier.
36. The method of claim 35, wherein the serotonin-related disorder
is a 5-HT2C-receptor related disorder.
37. The method of claim 35, wherein the serotonin-related disorder
is obesity or type II diabetes.
38. The method of claim 35, wherein the mammal is a human.
39. The method of claim 35, wherein treating the serotonin-related
disorder comprises alleviating at least one symptom of the
serotonin-related disorder.
40. The method of claim 35, wherein the pharmaceutical composition
is administered orally.
41. The method of claim 35, wherein the pharmaceutical composition
is administered parenterally.
42. A method of treating obesity in a subject in need of such
treatment, comprising administering to the subject a
therapeutically effective amount of a pharmaceutical composition
comprising a compound of formula (I): ##STR00013## wherein
R.sub.1-R.sub.4 are hydrogen and HA is L-malic acid; and a
pharmaceutically acceptable carrier.
43. The method of claim 42, wherein the pharmaceutical composition
is administered orally.
44. The method of claim 42, wherein the subject is a human.
45. A method of treating type II diabetes in a subject in need of
such treatment, comprising administering to the subject a
therapeutically effective amount of a pharmaceutical composition
comprising a compound of formula (I): ##STR00014## wherein
R.sub.1-R.sub.4 are hydrogen and HA is L-malic acid; and a
pharmaceutieally acceptable carrier.
46. The method of claim 45, wherein the pharmaceutical composition
is administered orally.
47. The method of claim 45, wherein the pharmaceutical composition
is administered parenterally.
48. The method of claim 45, wherein the subject is a human.
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser.
No. 12/817,833, filed Jun. 17, 2010, which is a continuation of
U.S. application Ser. No. 11/359,152, filed Feb. 22, 2006, which is
a divisional of U.S. application Ser. No. 10/464,181, filed Jun.
18, 2003, which claims priority to Swedish application number
0201881-0, filed on Jun. 19, 2002, Swedish application number
0202041-0, filed on Jun. 28, 2002, Swedish application number
0202516-1, filed on Aug. 26, 2002, U.S. provisional application
60/390,656, filed Jun. 21, 2002, U.S. provisional application
60/406,119, filed on Aug. 26, 2002, and U.S. provisional
application 60/416,701, filed on Oct. 7, 2002, the contents of
which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to a process for the
preparation of compounds which are therapeutically active in the
central nervous system.
BACKGROUND OF THE INVENTION
[0003] Many diseases of the central nervous system are influenced
by the adrenergic, the dopaminergic, and the serotonergic
neurotransmitter systems. For example, serotonin has been
implicated in a number of diseases and conditions which orginiate
in the central nervous system. A number of pharmacological and
genetic experiments invo9lving receptors for serotonin strongly
implicate the 5-HT.sub.2c receptor subtype in the regulation of
food intake (Obes. Res. 1995, 3, Suppl. 4, 449S-462S). The
5-HT.sub.2c receptor subtype is transcribed and expressed in
hypothalmic structures associated with appetite regulation. It has
been demonstrated that the non-specific 5-HT.sub.2c receptor
agonist m-chlorophenylpiperazine (mCPP), which has some preference
for the 5-HT.sub.2c receptor, causes weight loss in mice that
express the normal 5-HT.sub.2c receptor while the compound lacks
activity in mice expressing the mutated inactive form of the
5-HT.sub.2c receptor while the compound lacks activity in mice
expressing the mutated inactive form of the 5-HT.sub.2c receptor
(Nature 1995, 374, 542-546). In a recent clinical study, a slight
but sustained reduction in body weight was obtained after 2 weeks
of treatment with mCPP in obese subjects (Psychopharmacology 1997,
133, 309-312). Weight reduction has also been reported from
clinical studies with other "serotonergic" agents (see e.g. IDrugs
1998, 1, 456-470). For example, the 5-HT reuptake inhibitor
fluoxetine and the 5-HT releasing agent/reuptake inhibitor
dexfenfluramine have exhibited weight reduction in controlled
studies. However, currently available drugs that increase
serotonergic transmission appear to have only a moderate and, in
some cases, transient effects on the body weight.
[0004] The 5-HT.sub.2c receptor subtype has also been suggested to
be involved in CNS disorders such as depression and anxiety (Exp.
Opin. Invest. Drugs 1998, 7, 1587-1599; IDrugs, 1999, 2,
109-120).
[0005] The 5-HT.sub.2c receptor subtype has further been suggested
to be involved in urinary disorders such as urinary incontinence
(IDrugs, 1999, 2, 109-120).
[0006] Compounds which have a selective effect on the 5-HT.sub.2c
receptor may therefore have a therapeutic potential in the
treatment or prophylaxis of disorders like those mentioned above.
Of coarse, selectivity also reduces the potential for adverse
effects mediated by other serotonin receptors.
[0007] Examples of such compounds are
(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpipe-
razine,
(2R)-methyl-1-[3-[2-(3-pyridinyloxy]ethoxy]-2-pyrazinyl)piperazine
and pharmaceutically acceptable acid salts thereof. WO 00/76984
(hereinafter called D1) relates to a process for the preparation of
such compounds on a small scale such as a gram scale. A problem to
be solved by the present invention was to prepare such compounds on
a large scale such as on a kilogram scale. The following factors
are more important for preparation on a large scale, in comparison
to preparation on a small scale: [0008] to obtain a high yield of
the desired products tor economy reasons, [0009] that the processes
for preparations are safe with regard to explosion, [0010] that the
reagents and solvents used are relatively non-toxic, [0011] that
the products obtained are relatively stable, and [0012] that the
reaction times are relatively short.
[0013] These problems have been solved by the present invetrtlon.
It has been shown that the yields of the desired products according
to the present invention are higher than the yields according to
D1. In the experimental part, the yields according to the present
invention and D1 are compared. Regarding the choice of solvents for
the process steps, dioxane, as used according to D1, has been
replaced by solvents such as MtBE and THF (see step (ii) below)
which are less prone to form peroxides and which are less
carcinogenic than dioxane. Furthermore, it has been shown that
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
L-malate salt prepared according to the present invention (see
Example 3A) has superior properties compared to
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
hydrochloride prepared according to D1 in that the former has a
higher crystallinity, is less hygroscopic and has a higher chemical
stability than the latter. Regarding chemical stability, D1
discloses the preparation of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine, which has also
been prepared in Example 8 below. This compound is not stable for
storage as a free base. As
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine is a key
intermediate, chemical stability during long term storage is
important with regard to process economy. It has now been found
that the corresponding hydrochloride salt thereof is considerably
more stable, which has been prepared in Example 9 below.
[0014] The method to prepare Example 3C is a good way of increasing
the purity of Example 2C. It hay been shown that Example 2C with a
purity of 60-70% gives Example 3C with a purity of 99% in one
crystallization step. By contrast, the same purity increasing
effect has not been achieved by making the acetate of Example
2C.
[0015] Regarding reaction time, the reaction according to Example
2A below was complete at room temperature in 15 minutes. The same
compound has been prepared in Example 173 in D1. The procedure of
Example 172, step 3 has been followed, wherein the reaction was
stirred at 85.degree. C. for 15 h. Furthermore, the reaction
according to Example 2B below was complete in 35 minutes at
55.degree. C. The same compound has been prepared in Example 200 in
D1. The procedure of Example 192, step 3 has been followed, wherein
the reaction was stirred at 90.degree. C. for 2 h.
SUMMARY OF THE INVENTION
[0016] One object of the present invention is a process for the
preparation of compounds which bind to the 5-HT.sub.2c receptor
(agonists and antagonists) and which therefore may be used for the
treatment or prophylaxis of serotonin-related disorders.
[0017] In one aspect, the invention relates to a process for the
preparation of compounds of the general formula (I):
##STR00002##
comprising the steps of: [0018] (i) hydroxyalkylating (i.e.,
O-alkylating) a 3-pyridinol derivative of the general formula (II)
or the corresponding hydrochloride:
##STR00003##
[0018] to give another 3-pyridinol derivative of the general
formula (III):
##STR00004## [0019] (ii) condensing the 3-pyridinol derivative of
the general formula (III) with
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpyrazine of the formula (IV)
in the presence of an alkali metal tert-butoxide (e.g. potassium
tert-butoxide) or an alkali earth metal tert-butoxide, as a base in
a solvent system (e.g., a solvent system containing
tetrahydrofuran),
##STR00005##
[0019] to give a compound of the general formula (V):
##STR00006## [0020] (iii) which is then converted to the compound
of the general formula (I) by treatment with a pharmaceutically
acceptable acid of the formula HA, wherein R.sub.1-R.sub.4 are each
independently selected from the group consisting of hydroge,
halogen, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, and
di-C.sub.1-C.sub.6-alkylamino-C.sub.2-C.sub.6-alkoxy; and wherein
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpyrazine of the formula (IV)
is prepared by: [0021] (iv) acidification of racemic
2-methylpiperazine of the formula (VI):
##STR00007##
[0021] with L-tartaric acid and fractional crystallization to give
(R)-2-methylpiperazine, L-tartrate of the formula (VII):
##STR00008## [0022] (v) basification of (2R)-2-methylpiperazine,
L-tartrate of the formula (VII) to give (R)-2-methylpiperazine of
the formula (VIII):
[0022] ##STR00009## [0023] (vi) tritylation of
(R)-2-methylpiperazine of the formula (VIII) to give
(R)-3-methyl-1-tritylpiperazine of the formula (IX):
[0023] ##STR00010## [0024] (vii) condensation of
(R)-3-methyl-1-tritylpiperazine of the formula (IX) with
2,3-dichloropyrazine to give
(2R)-1-(3-chloro-2-pyrazinyl)-2-methyl-4-tritylpiperazine of the
formula (X):
[0024] ##STR00011## [0025] (viii) detriylation of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methyl-4-tritylpiperazine of the
formula (X) to give
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV), [0026] (ix) and conversion of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV) to a suitable acid addition salt (e.g., hydrochloride
salt).
[0027] It is preferred that R.sub.1-R.sub.3 are hydrogen and
R.sub.4 is selected from the group consisting of hydrogen, ethoxy,
and 2-dimethylaminoethoxy.
[0028] It is also preferred that: [0029] step (iv) is performed by
using water and ethanol as solvents; [0030] step (v) is performed
by using a hydroxide (e.g., sodium hydroxide) as a base; [0031]
step (vi) is performed with trityl chloride in the presence of
triethylamine; [0032] step (vii) is performed in the presence of an
alkali metal carbonate (e.g., potassium carbonate) or an alkali
earth metal carbonate, with dimetyhyl formamide as a solvent; and
[0033] step (viii) is performed in 10% sulfuric acid in
ispropanol.
[0034] When R.sub.1-R.sub.4 are hydrogen, it is preferred that:
[0035] step (i) is performed by reacting the compound of the formul
(II) with ethylene carbonate with an alkali metal carbonate (e.g.
potassium carbonate) or an alkali earth metal carbonate, as a base
and dimethyl formamide as a solvent, [0036] step (ii) is performed
by reacting the coumpound of the formula (III) with the compound of
the formula (IV) in the preface of an alkali metal tert-butoxide
(e.g. potassium tert-butoxide) or an alkali earth metal,
tert-butoxide, in tetrahydrofuran, [0037] the pharmaceutically
acceptable acid of the formula HA in step (iii) is L-malic acid.
Before converting the compound of the formula (i), wherein
R.sub.1-R.sub.4 are hydrogen, into the L-malate salt, the product
of the formula (V) is preferably converted to the fumarate, giving
a more pure product. After that, the fumarate may be converted to
the L-malate, e.g. via neutralization of the fumarate with a base
and then converted to the L-malate by means of L-malic acid.
[0038] When R.sub.1-R.sub.3 are hydrogen and R.sub.4 is ethoxy, it
is preferred that: [0039] step (i) is performed by reacting the
hydrochloride of the compound of the formula (II) with
2-chloroethanol with in an aqueous solution of a hydroxide, more
preferably sodium hydroxide. [0040] step (ii) is performed by
reacting the compound of the formula (III) with the composed of the
formula (IV) in the presence of an alkali metal tert-butoxide (e.g.
potassium tert-butoxide) or an alkali earth metal tert-butoxide, in
a solvent system consisting of methyl tert-butylether and
tetrahydrofuran, [0041] the pharmaceutically acceptable acid of the
formula HA in step (iii) is succinic acid.
[0042] When R.sub.1-R.sub.3 are hydrogen and R.sub.4 is
2-dimethylaminoethoxy, it is preferred that: [0043] step (i) is
performed by reacting the compound of the formula (II) with
ethylene carbonate with an alkali metal carbonate (e.g. potassium
carbonate) or an alkali earth metal carbonate, as a base and
dimethyl sulfoxide as a solvent, [0044] step (ii) is performed by
reacting the compound of the fonnula (III) with the compound of the
formula (IV) in the presence of an alkali metal tert-butoxide (e.g.
potassium tert-butoxide) or an alkali earth metal tert-butoxide, in
tetrahydrofuran, [0045] the pharmaceutically acceptable acid of the
formula HA in step (iii) is phosphoric acid.
[0046] This invention also features a process for the preparation
of compounds of the general formula (I). The process includes the
steps of: [0047] (i) reacting a 3-pyridinol derivative of the
general formula (II) or the corresponding hydrochloride with
ethylene carbonate, to give another 3-pyridinol derivative of the
general formula (III): [0048] (ii) reacting the 3-pyridinol
derivative of the general formula (III) with
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV) in the presence of an alkali metal tert-butyxide (e.g.,
potassium tert-butoxide) or an alkali earth metal tert-butoxide, to
give a compound of the general formula (V), [0049] (iii) converting
the compound of the general formula (V) to the compund of the
general formula (I) by treatment with a pharmaceutically)
acceptable acid of the formula HA (e.g., L-malic acid), wherein
each of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is hydrogen, Step
(i) can be performed in the presence of as alkali metal carbonate
(e.g. potassium carbonate) or an alkali earth metal carbonate as a
base, and dimethyl formamide as a solvent; and step (ii) can be
performed by reacting the compound of the general formula (III)
with the composed of the formula (IV) in tetrahydrofuran.
[0050] In this process,
(2R)-1-(3-chloro-2-pyrazinyl)-1methylpiperazine of the formula (IV)
can be prepared by: [0051] (iv) acidification of racemic
2-methylpiperazine of the formula (VI) with L-tartaric acid and
fractional crystallization to give (R)-2-methylpiperazine,
L-tartrate of the formula (VII): [0052] (v) basification of
(2R)-2-methylpiperazine, L-tartrate of the formula (VII) to give
(R)-2-methylpiperazine of the formula (VIII): [0053] (vi)
triylation of (R)-2-methylpiperazine of the formula (VIII) to give
(R)-3-methyl-1-triylpiperazine of the formula (IX), [0054] (vii)
condensation of (R)-3-methyl-1-tritylpiperazine of the formula (IX)
with 2,3-dichloropyrazine to give
(2R)-1-(3-chloro-2-pyrazine)-2-methyl-4-tritylpiperazine of the
formula (X); [0055] (viii) ditrtylation of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methyl-4-tritylpiperazine of the
formula (X) to give
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV), [0056] (ix) and conversion of
(2R-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula (IV)
to a suitable acid addition salt (e.g., hydrochloride salt). The
formula (I) to (X) are the same as described above.
[0057] This invention further features a process for the
preparation of compounds of the general formula (I). The process
includes the steps of: [0058] (i) O-alkylatina a 3-pyridinol
derivative of the general formula (II) or the corresponding
hydrochloride, to give another 3-pyridinol derivative of the
general formula (III), [0059] (ii) reacting the 3-pyridinol
derivative of the general formula (III) with
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV) in the presence of potassium tert-butoxide, to give a compound
of the general formula (V), [0060] (iii) converting the compound of
the general formula (V) to the compound of the general formula (I)
by treatment with a pharmaceutically acceptable acid of the formula
HA (e.g., succinic acid), wherein each of R.sub.1, R.sub.2, and
R.sub.3 is hydrogen, R.sub.4 is C.sub.1-C.sub.6-alkoxy (e.g.,
ethoxy). Step (i) can be performed by reacting the hydrochloride of
the compound of the general formula (II) with 2-chloroethanol in an
aqueous solution of a hydroxide (e.g., sodium hydroxide), and step
(ii) can be performed by reacting the compound of the general
formula (III) with the compound of the formula (IV) in a solvent
system consisting of methyl tert-butylether and
tetrahydrofuran.
[0061] This invention also features a process for the preparation
of compounds of the general formula (I). The process includes the
steps of: [0062] (i) reacting a 3-pyridinol derivative of the
general formula (II) or the corresponding hydrochloride with
ethylene carbonate, to give another 3-pyridinol derivative of the
general formula (III): [0063] (ii) reacting the 3-pyridinol
derivative of the general formula (III) with
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV) in the presence of an alkali metal tert-butoxide (e.g.,
potassium tert-butoxide) or an alkali earth metal tert-butoxide, to
give a compound of the general formula (V), [0064] (iii) converting
the compound of the general formula (V) to the compound of the
general formula (I) by treatment with a pharmaceutically acceptable
acid of the formula HA (e.g., phosphoric acid), wherein each of
R.sub.1, R.sub.2, and R.sub.3 is hydrogen, R.sub.4 is
di-C.sub.1-C.sub.6-alkylamino-C.sub.2-C.sub.6-alkoxy (e.g.,
2-dimethylaminoethoxy). Step (i) can be performed in the presence
of an alkali metal carbonate (e.gt., potassium carbonate) or an
alkali earth metal carbonate as a base, and dimethyl sulfoxide as a
solvent; and step (ii) can be performed by reacting the compound of
the general formula (III) with the compound of the formula (IV) in
tetrahydrofuran.
[0065] Another object of the present invention is a process for
preparing (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine,
hydrochloride by reacting
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine of the formula
(IV) with hydrochloric acid.
[0066] Another object of the present invention is the compound
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine,
hydrochloride.
[0067] Another object of the present invention is a compound of the
formula (I), wherein R.sub.1-R.sub.4 are hydrogen and HA is L-malic
acid.
[0068] Another object of the present invention is a compound of the
formula (I), wherein R.sub.1-R.sub.3 are hydrogen, R.sub.4 is
ethoxy and HA is succinic acid.
[0069] Another object of the present invention is a compound of the
formula (I), wherein R.sub.1-R.sub.3 are hydrogen, R.sub.4 is
2-dimethylaminoethoxy, and HA is phosphoric acid.
[0070] Also within the scope of this invention is a method for the
treatment or prophylaxis of a serotonin-related disorder,
particularly 5-HT.sub.2C receptor related. The method includes
administering to a subject in need thereof an effective amount of a
compound of the formula (I), wherein R.sub.1-R.sub.3 are hydrogen,
R.sub.4 is selected from hydrogen, ethoxy, and
2-dimethylaminoethoxy, and HA is selected from L-malic acid,
succinic acid, and phosphoric acid. Examples of such disorders are
obesity and type II diabetes.
[0071] Also within the scope of this invention is the use of a
compound of formula (I), wherein R.sub.1-R.sub.3 are hydrogen,
R.sub.4 is selected from hydrogen, ethoxy, and
2-dimethylaminoethoxy, and HA is selected from L-malic acid,
succinic acid, and phosphoric acid, to manufacture a medicament for
the treatment or prophylaxis of a serotonin-related disorder,
particularly 5-HT.sub.2C receptor related. Examples of such
disorders are obesity and type II diabetes.
[0072] Another aspect is a method of making a composition
comprising combining a compound of formula (I) (including those
made by the processes delineated herein) with a pharmaceutically
acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION
[0073] Below, the various terms used in the above definition of the
compounds of the compounds of the general formulas (I)-(V) will be
explained.
[0074] C.sub.1-C.sub.6-alkyl is a straight or branched alkyl group
having 1-6 carbon atoms. Exemplary alkyl groups include methyl,
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl,
n-pentyl, isopentyl, n-hexyl, and isohexyl.
[0075] For parts of the range "C.sub.1-C.sub.6-alkyl" all subgroups
thereof are contemplated such as C.sub.1-C.sub.5-alkyl,
C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.3-alkyl,
C.sub.1-C.sub.2-alkyl, C.sub.2-C.sub.6-alkyl,
C.sub.2-C.sub.5-alkyl, C.sub.2-C.sub.4-alkyl,
C.sub.2-C.sub.3-alkyl, C.sub.3-C.sub.6-alkyl,
C.sub.4-C.sub.5-alkyl, etc.
[0076] C.sub.1-C.sub.6-alkoxy is a straight or branched alkyl group
having 1-6 carbon atoms. Exemplary alkoxy groups include methoxy,
ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy,
n-pentoxy, isopentoxy, n-hexoxy, and isohexoxy.
[0077] For parts of the range "C.sub.1-C.sub.6-alkoxy" all
subgroups thereof are contemplated such as C.sub.1-C.sub.5-alkoxy,
C.sub.1-C.sub.4-alkoxy, C.sub.1-C.sub.3-alkoxy,
C.sub.1-C.sub.2-alkoxy, C.sub.2-C.sub.6-alkoxy,
C.sub.2-C.sub.5-alkoxy, C.sub.2-C.sub.4-alkoxy,
C.sub.2-C.sub.3-alkoxy, C.sub.3-C.sub.6-alkoxy,
C.sub.4-C.sub.5-alkoxy, etc.
[0078] The term "DSC" in the present description means
"differential scanning calorimetry".
[0079] The term "DVS" in the present description means "dynamic
vapor sorption gravimetry".
[0080] The term "FBE" in the present description means "free base
equivalents".
[0081] The term "halogen" in the present description is intended to
include fluorine, chlorine, bromine and iodine.
[0082] The term "IDR" in the present description means "intrinsic
dissolution rate".
[0083] The term "IP" in the present description means "in
process".
[0084] The term "NLT" in the present description means "not less
than".
[0085] "Pharmaceutically acceptable acid salts" mean salts which
are pharmaceutically acceptable, as defined above, and which
possess the desired pharmacological activity. Such salts include
acid addition salts formed with any organic and inorganic
pharmaceutically acceptable acid ("HA"), such as hydrogen chloride,
hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid,
acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid,
toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid,
fumaric acid, succinic acid, malic acid, tartaric acid, citric
acid, benzoic acid, ascorbic acid and the like.
[0086] DMF means dimethyl formamide, DMSO means dimethyl sulfoxide,
IPA means isopropanol, MtBE means methyl tert-butyl ether, RH means
relative humidity, RT means room temperature, t-BuOK means
tert-butyl alcohol, potassium salt, THF means tetrahydrofuran, and
trityl means triphenylmethyl.
[0087] It should be noted that both E- and Z-isomers of the
compounds, optical isomers, as well as mixtures thereof, and all
isotopes are included within the scope of the invention. By the
expression "isotopes" is meant all compounds with naturally
occurring isotopes such as all possible deuterium and
.sup.13C-isotopes of the compounds according to the invention. The
compounds of the present invention may also contain unnatural
proportions of atomic isotopes at one or more of the atoms that
constituted such compounds. For example, the compounds may be
radiolabelled with radioactive isotopes, such as fore example
tritium (.sup.3H), .sup.125I or .sup.14C. All isotopic variations
of the compounds of the present invention, whether radioactive or
not, are intended to be encompassed within the scope of the present
invention.
[0088] The chemicals used in the above-described synthetic routes
may include, for example, solvents, reagents, catalysts, protecting
group and deptoteeting group agents. The methods described above
may also additionally include steps, either before or after the
steps described specifically herein, to add or remove suitable
protecting groups in order to ultimately allow synthesis of the
compounds of the formula (I). Synthetic chemistry transformations
and protecting group methodologies (protection and de-protection)
useful in synthesizing applicable compounds of the formula (I) are
known in the art and include, for example, those described in R.
Larock, Comprehensive Organic Transformations, VCH Publishers
(1989); T. W. Greene and P. G. M. Wuts; Protective Groups in
Organic Synthesis, 2.sup.nd Ed., John Wiley and Sons (1991); L.
Fieser and M. Fieser. Fieser and Fieser's Reagents for Organic
Synthetic, John Wiley and Sons (1994); and L. Paquette, ed.,
Encyclopedia of Reagents for Organic Synthesis; John Wiley and Sons
(1995) and subsequent editions thereof.
[0089] In accordance with the present invention, the compound of
the formula (I), wherein R.sub.1-R.sub.3 are hydrogen, R.sub.4 is
selected from hydrogen, ethoxy or 2-dimethylaminoethoxy and HA is
selected from L-malic acid, succinic acid, and phosphoric acid, can
be brought into suitable galenic forms, such as compositions for
oral use, for injection, for nasal spray administration or the
like, in accordance wills accepted pharmaceutical procedures. Such
pharmaceutical compositions according to the invention comprise an
effective amount of the aforementioned compound in association with
compatible pharmaceutically acceptable carrier materials, or
diluents, as are well known in the art. The carriers may be any
inert material, organic or inorganic suitable for enteral,
percutaneous, subcutaneous or parenteral administration, such as:
water, gelatin, gum arabicum, lactose, microcrystalline cellulose,
starch, sodium starch glycolate, calcium hydrogen phosphate,
magnesium stearate, talcum, colloidal silicon dioxide, and the
like. Such compositions may also contain other pharmacologically
active agents, and conventional additives, such as stabilizers,
wetting agents, emulsifiers, flavouring agents, buffers, and the
like.
[0090] The compositions according to the invention can e.g. be made
up in solid or liquid form for oral administration, such as
tablets, pills, capsules, powders, syrups, elixirs, dispersable
granules, cachets, suppositories and the like, in the form of
sterile solutions, suspensions or emulsions for parenteral
administrations, sprays, e.g. a nasal spray, transdermal
preparations, e.g. patches, and the like.
[0091] As mentioned above, the aforementioned compounds of the
invention may be used for the treatment or prophylaxis of a subject
(e.g., a human or an animal) suffering from a serotonin-related
disorder or conditions, particularly 5-HT.sub.2C receptor related,
such as memory disorders, such as Alzheimer's disease;
schizophrenia; mood disorders such as depression; anxiety
disorders; pain; substance abuse; sexual dysfunctions such as
erectile dysfunction; epilepsy; glaucoma; urinary disorders, such
as urinary incontinence; menopausal and post-menopausal hot
flushes; eating disorders, such as binge eating disorders, anorexia
nervosa and bulimia; weight gain associated with antipsychotic drug
administration, type II diabetes; and particularly obesity.
[0092] The method of treatment or prophylaxis includes
administering to a subject in need of treatment an effective amound
of the compound of this invention. The term "treating" or "treated"
refers to administering a compound of this invention to a subject
with the purpose to cure, heal, alleviate, relieve, alter, remedy,
ameliorate, improve, or affect a disease, the symptoms of the
disease or the predisposition toward the disease. "An effective
amount" refers to an amount of a compound which confers a
therapeutic effect on the treated subject. The therapeutic effect
may be objective (i.e., measurable by some test or marker) or
subjective (i.e., subject gives an indication of or feels an
effect). The dose level and frequency of dosage of the specific
compound will vary depending on a variety of factors including the
potency of the specific compound employed, the metabolic stability
and length of action of that compound, the patient's age, body
weight, general health, sex, diet, mode and time of administration,
rate of excretion, drug combination, the severity of the condition
to be treated, and the patient undergoing therapy. The daily dosage
may, for example, range from about 0.01 mg to about 100 mg per kilo
of body weight, administered singly or multiply in doses, e.g.,
from about 0.01 mg to about 25 mg each. Normally, such a dosage is
given orally but parenteral administration may also be chosen.
[0093] The invention also refers to the use of the aforementioned
compounds to manufacture a medicament for the treatment or
prophylaxis of a serotonin-related disorder, particularly
5-HT.sub.2C receptor related.
[0094] All publications mentioned herein are hereby incorporated by
reference. By the expression "comprising" we understand including
but not limited to.
[0095] The invention will now be illuminated by the following
Examples, which one only intended to illuminate and not restrict
the invention in any way. Examples 1A-3A illustrate steps (i)-(iii)
when R.sub.1-R.sub.4 are hydrogen. Examples 1B-3B illustrate steps
(i)-(iii) when R.sub.1-R.sub.3 are hydrogen and R.sub.4 is ethoxy.
Examples 1C-3C illustrate steps (iv)-(iii) when R.sub.1-R.sub.3 are
hydrogen and R.sub.4 is 2-dimethylaminoethoxy. Examples 4-8
illustrate steps (iv)-(viii) when R.sub.1-R.sub.3 are hydrogen and
R.sub.4 is selected from the group consisting of hydrogen, ethoxy,
and 2-dimethylaminoethoxy. Regarding the compound of the formula
(IV) as prepared its step (viii), it has been shown that this
compound is not stable for storage as a free base. However, the
corresponding hydrochloride thereof is considerably more stable.
Example 9 describes the preparation of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine, hydrochloride.
Furthermore, the properties of different salts of the formula (I)
were evaluated. Example 10 describes the preparation of
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
fumarate. By making the fumarate in Example 10, a more pure
product, is obtained before converting to the L-malate salt
(prepared in Example 2A). Example 11 describes the comparison of
the properties of different salts of Example 2A. Example 12
describes the comparison of the properties of different salts of
Example 2B. Example 13 describes the comparison of the properties
of different salts of Example 2C.
EXAMPLES
General
[0096] 2-ethoxy-3-hydroxypyridine, HCl (for Example 1B) and
2-(2-dimethylaminoethoxy)pyridin-3-ol (for Example 1C) were
purchased from Nordic Synthesis in Karlskoga, Sweden. The other
chemicals mentioned are commercially available and could e g be
purchased from Alrich. For Examples 1B-3B, HPLC analysis confirmed
that the desired products were obtained. The HPLC pump was a Varian
9012. A Varian 9050 detector at 220 nm was used. The eluent was 80
mM KH.sub.2PO.sub.4 in a 80:20 mixture of water/acetonitrile. The
column was a Varian C8, 150.times.4.5 mm. For Examples, 1C-3C, HPLC
analysis also confirmed that the desired products were obtained.
The eluent was A: 0.1% trifluoroacetic acid in water, B:
acetonitrile; increasing percentage of acetonitrile during 3
minutes. The column was a YMC FL-ODS AQ S-5.mu., 12 nm,
50.times.4.6 mm (Example 1C) and a Hypersil BDS C18, 3.mu.,
30.times.4.6 mm (Example 2C-3C), respectively.
Example 1A
Preparation of 2-(3-pyridinyloxy)ethanol
[0097] 3-hydroxypyridine (20.0 kg), ethylene carbonate (19.4 kg),
K.sub.2CO.sub.3), (18.9 kg), and DMF (75.5 kg) were charged to a
400 L reactor and heated to 86.degree. C. After 13 h, an aliquot
was taken. There was still some 3-hydroxypyridine let by GC so more
ethylene carbonate (1.0 kg) was added. After 20 h, the reaction wax
deemed complete. The reaction was cooled to 20.degree. C., H.sub.2O
(85 L) was slowly added to the 400 L reactor, and stirring
continued for 30 min. The title compound was extracted with
35.degree. C. CH.sub.2Cl.sub.2 (4.times.170 L) sending the
CH.sub.2Cl.sub.2 extractions into the 1000 L portable tank. The
aqueous layer was discarded, and the 400 L reactor was cleaned. The
solution of the title compound in the 1000 L portable tank was
transferred to the 400 L and distilled in the 400 L reactor sending
the distillate to the 400 L receiver. Toluene (200 L) was added so
the 400 L reactor and distilled sending the distillate to the 400 L
receiver. The resulting oil was transferred to a 20 L, glass bottle
to produce 21.0 kg (72%) of the title compound of 100.0% GC
purity.
[0098] The yield of the title compound according to D1, starting
from 3-hydroxypyridine, 2-chloroethanol and K.sub.2CO.sub.3 in DMF
was 19%. The title compound has also been prepared according to EP
0 216 242 A2 starting from methyl [(3-pyridimyl)oxy]acetate.
[0099] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.30 (1H, br s),
8.20 (1H, t, J=3.1 Hz), 7.23 (2H, t, J=2.1 Hz), 4.13 (2H, t, J=4.6
Hz), 3.99 (2H, t, J=4.6 Hz), 3.76 (1H, br s), 0.00 (TMS,
reference),
[0100] .sup.13C NMR (100 MHz, CDCl.sub.3): .delta. 155.09 (s),
142.09 (d), 137.95 (d), 121.32 (d), 69.83 (t), 60.98 (t), 0.00
(TMS, reference).
[0101] IR (liq.) 2382 (w), 2082 (w), 1996 (w), 1954 (w), 1587, 1576
(s), 1488, 1478 (s), 1429 (s), 1272 (s), 1235 (s), 1084, 1054 (s),
802, 707 (s), cm.sup.-1.
[0102] Anal. Calcd for C.sub.7H.sub.9NO.sub.2: C, 60.42: H, 6.52;
N, 10.07, Found: C, 60.14; H, 6.51; N, 10.39. HRMS (FAB) calcd for
C.sub.7H.sub.9NO.sub.2 +H.sub.1 140.0712. found 140.0705.
Example 1B
Preparation of 2-[(2-ethoxy-3-pyridinyl)oxy]ethanol
[0103] To water (30.0 kg) was added 3.40 kg of NaOH. The resulting
suspension was stirred until complete dissolution had occurred. The
temperature of the solution was then adjusted to approx. 60.degree.
C. To the alkaline solution was carefully added
2-ethoxy-3diydroxypyridine, HCl (6.00 kg). The temperature was
raised to 85.0.degree. C. and the mixture stirred for 30 min to
allow for complete dissolution. During 85 min, 2-chloroethanol
(4.10 kg) was added, while the temperature was kept between
88.0-92.0.degree. C. The reaction was allowed to age for 50 min at
approx. 90.degree. C., after which time HPLC indicated complete
conversion of 2-ethoxy-3-hydroxypyridine, HCl to the title
compound. The reaction mixture was poured into 65.1 kg of methyl
tert-butylether (MtBE). The reaction vessel was rinsed with water
(2.0 kg). To the resulting two-phase system was added 3.05 kg of
NaCl and 0.20 kg of NaOH. The resulting mixture was stirred for 55
min, while the temperature was lowered to 24.9.degree. C. The
mixture was the allowed to stir for another 20 min at
23.7-24.9.degree. C. The water phase was removed. The remaining
organic phase was concentrated by distillation at atmospheric
pressure. When 45 L had been removed, the residue was cooled to
room temperature and transferred to a drum. The residue weighed
33.1 kg. According to HPLC, the assay is 118.9 g of the title
compound per kg of mixture, corresponding to a yield of 6.25 kg
(quantitative yield) of pure title compound.
[0104] The yield of the title compound according to D1, starting
from 2-bromo-3-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)pyridine
and sodium ethoxide in ethanol was 41%.
Example 1C
Preparation of
2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethanol
[0105] DMSO (17 L) and potassium carbonate (8.2 kg) were charged to
the 100 L-glasslined reactor. The mixture was heated to 58.degree.
C. while stirring. 2-(2-Dimethylaminoethoxy)pyridin-3-ol (4.11 kg)
was charged to the reactor during 23 minutes (gas evolution). The
mixture was heated to 117.degree. C. before the prepared ethylene
carbonate solution was added through the manhood in portions. After
1 L ethylene carbonate solution was added IP-HPLC was taken to
ensure that the title compound had started to form. The total
addition of ethylene carbonate solution was made during 1 h 35
minutes. Temperature after the addition was 124.degree. C. A HPLC
sample was taken from the reaction mixture 10 minutes after
finished addition. It showed 95% conversion to product. The
reaction mixture was allowed to cool to 70.degree. C. before water
(45 L) and sodium chloride (4.06 kg) was charged to the reactor.
The mixture was then stirred for 20 minutes at 70.degree. C. before
cooled to RT. Ethyl acetate (137 L) was charged into a 328 L
glass-lined reactor. The wafer mixture was transferred from the 100
L reactor to the 328 L reactor. The mixture was stirred for 25
minutes before the mechanical stirrer was turned off. After
allowing the phases to separate for 40 minutes, the water-phase (65
L) was discharged. The mixture was heated to reflux and 102 L of
ethyl acetate was distilled off. Toluene (72 L) was added and the
mixture was heated to reflux again and 61 L of toluene/ethyl
acetate was distilled off. The reaction mixture was then cooled to
RT. The title compound was never isolated; it was directly used in
Example 2C.
[0106] The preparation of the title compound has not been described
in D1.
Example 2A
Preparation of
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine
[0107] A 400 L reactor containing a toluene solution of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine (for preparation
of this compound, see Example 8 below) was distilled to remove
toluene, THE (40 kg) was added, and the slurry was stirred until
all the oil dissolved. The solution was transferred to a drum with
a THF rinse (10 kg). The THF/toluene solution of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine (ca 9.7 kg thereof
in 90.4 kg solution) was transferred to a 1200 L reactor with a THF
rinse (4 L). 2-(3-pyridinyloxy)ethanol from Example 1A (7.6 kg) was
transferred to the 1200 L reactor with a THF rinse (34 L) and
stirred at room temperature for 15 min. 20 wt % KOt-Bu (33.3 kg)
was added followed by a THF rinse (4 kg). The reaction was
monitored by GC and was complete in 15 min. The reaction in the
1200 L reactor was quenched with H.sub.2O (119 L) and extracted
with CH.sub.2Cl.sub.2 (1.times.215 L, 2.times.117 L) sending the
CH.sub.2Cl.sub.2 extractions into the 800 L receiver. The
CH.sub.2Cl.sub.2 solution was transferred to the 1200 L reactor and
the CH.sub.2Cl.sub.2 was removed by distillation. A solvent swap
distillation using MeOH (2.times.215 L) was performed distilling to
a volume of 100 L. The MeOH solution of the title compound was
filtered through a bag filter containing carbon (5 kg) recycling
the solution four times from the 1200 L reactor to the 800 L
receiver. The solution in the 800 L receiver was transferred to the
1200 L reactor with a MeOH rinse (50 L). The solution was distilled
to a final volume of 70 L and transferred to a drum with a MeOH
rinse (10 L) in preparation for the compound in Example 3A. The
yield was quantitative.
[0108] The yield of the hydrochloride of title compound according
to D1, starting from
3-chloro-2-[4-tert-butoxycarbonyl-(2R)-methyl-1-piperazinyl]pyrazine
and 2-(3-pyridinyloxy)ethanol with potassium tert-butoxide in
dioxane was 31%.
[0109] .sup.1H NMR (400 MHz, CDCl.sub.3); .delta. 8.35 (1H, br s),
8.25 (1H, t, J=3.0 Hz), 7.74 (1H, d, J=3.0 Hz), 7.49 (1H, d, J=2.5
Hz), 7.23 (2H, br t, J=2.3 Hz), 4.76 (1H, dt, J=12.2, 4.8 Hz), 4.67
(1H, dt, J=11.7 Hz, 5.2 Hz), 4.49-4.43 (1H, m), 4.40 (2H, t, J=4.8
Hz), 3.72 (1H, br d, J=12.8 Hz), 3.27 (1H, td, J=11.7, 3.0 Hz),
3.06 (1H, dd, J=12.3, 3.6 Hz), 2.99 (1H, br d, J=12.2 Hz), 2.88
(1H, td, J=11.7, 3.4 Hz), 2.75 (1H, br d, J=12.3 Hz), 1.72 (1H, br
s), 1.19 (3H, d, J=6.6 Hz), 0.00 (TMS, reference).
[0110] .sup.13C NMR (100 MHz, CDCl.sub.3); .delta. 154.86 (s),
150.35 (s), 147.30 (s), 142.60 (d), 138.09 (d), 134.14 (d), 129.89
(d), 123.87 (d), 121.17 (d), 66.54 (t), 63.97 (t), 50.86 (t), 49.52
(d), 46.22 (t), 42.78 (t), 14.26 (q), 0.00 (TMS, reference).
[0111] IR (liq.) 2068 (w), 1996 (w), 1576 (s), 1528 (s), 1475 (s),
1430 (s), 1330, 1276 (s), 1268 (s), 1246, 1208 (s), 1187 (s), 1181
(s), 1063, 708, cm.sup.-1.
[0112] HRMS (FAB) calcd for C.sub.16H.sub.21N.sub.5O.sub.2 +H.sub.1
316.1773, found 316.1777.
[0113] [.alpha.].sup.25.sub.D=-24.degree. (c 0.92, water).
[0114] Anal Calcd for C.sub.16H.sub.21N.sub.5O.sub.2: C, 60.94; H,
6.71; N, 22.21. Found: C, 59.98; H, 6.73; N, 22.40.
Example 2B
Preparation of
(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpipe-
razine
[0115] (2R)-1(3-chloro-2-pyrazinyl)-2-methylpiperazine (9.00 kg)
(see Example 8 for preparation) was dissolved in 20.1 kg of water
by stirring a room temperature for 25 min. Activated charcoal (0.50
kg) and celite (0.50 kg) was added. The resulting suspension was
stirred for 30 min at room temperature. The charcoal and celite was
removed by filtration under pressure. The filtered water-phase was
poured into 63.9 kg of MtBE (methyl tert-butylether). To the
resulting two-phase system were added NaOH (1.50 kg) and NaCl (4.40
kg). After stirring for 25 min at room temperature, the water phase
was discarded. The remaining organic phase was concentrated by
distillation at atmospheric pressure. A total of 45 L was removed.
To the remaining content of the reactor was added an MtBE-solution
of 2-[(2-ethoxy-3-pyridinyl)oxy]ethanol (one complete batch from
Example 1B). The resulting mixture is concentrated by distillation
at atmospheric pressure. A total of 40 L was removed. To the
residue, 40.8 kg of MtBE was added. Further concentration by
distillation was done with a total of 20 L being removed. A
solution of potassium tert-butoxide (KtBuO) was made by suspending
2.96 kg of KtBuO in 13.1 kg of THF. After stirring for 30 min at
room temperature almost everything was in solution. After emptying
the reactor, a second solution was made by in a similar way (3.02
kg of KtBuO to 13.0 kg of THF). The mixture of
2-[(2-ethoxy-3-pyridinyl)oxy]ethanol and
(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine was heated to
51.0.degree. C. To this mixture was added the solutions of KtBuO in
THF. During the addition, the temperature was kept between
50.7-55.6.degree. C. The total addition time was 50 min. After
aging for 35 min at 55.degree. C., HPLC indicated that the reaction
was complete. The reaction mixture was cooled to room temperature
and 23.1 kg of water was cautiously added while maintaining the
temperature below 25.degree. C. After stirring for 15 min at
approx. 23.degree. C., the water phase was discarded. The remaining
organic phase was concentrated by distillation at atmospheric
pressure. After 45 L had been removed, heptane (38.0 kg) was added.
Further distillation removed 50 L, followed by addition of heptane
(33.8 kg). By removing another 30 L via distillation, all remaining
MtBE had been removed from the heptane solution. To the residue,
20.8 kg of water was added and the temperature raised to
72.8.degree. C. After stirring for 15 min, the water phase was
removed at this temperature. The remaining solution was
concentrated by distillation at atmospheric pressure. A total of 50
L was removed. The residue was cooled to 50.5.degree. C. The
solution was seeded with 5.0 g of the title compound to induce
crystallization. The resulting suspension was stirred at
51.5.degree. C. for 35 min while maintaining maximum stirring
speed. Cooling was then continued to 8.2.degree. C. over night. The
product was isolated via filtration under suction. The resulting
product cake was washed with 11 L of heptane. The semi-dry cake
weighing 9.63 kg was dried at 40.degree. C./vakuum. The dried
product weight 8.1 kg (66%).
[0116] The yield of the fumarate of the title compound according to
D1, starting from (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine
and 2-[(2-ethoxy-3-pyridinyl)oxy]ethanol with sodium tert-butoxide
in dioxane was 17%.
Example 2C
Preparation of
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine
[0117] (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine (20 L in
toluene solution: see Example 8 for preparation) and active
charcoal (201 g) was added to the 328 L-reactor containing
2-{[2-(2-dimethylaminoethoxy)-3-pyradinyl]oxy}ethanol (Example 1C)
in toluene solution. The mixture was stirred for 25 minutes before
transferred to a through a GAF-filter (containing a Teflon filter
bag) to a 250 L-stainless steel reactor. The mixture was heated to
100.degree. C. before the prepared "THF/potassium
tert-butoxide-solution" was added to the reactor using a 50 L
addition bowl. After 10 L "THF/potassium tert-butoxide-solution"
was added, an IP-HPLC was taken to ensure that the title compound
had started to form. The total addition THF/potassium
tert-butoxide-solution was made during 2 h and 15 minutes. Water
(21 L) and sodium chloride (1 kg) was added to a 198 L-glasslined
reactor. The salt was dissolved before the reaction mixture was
transferred from the 328 L-reactor and quenched into the 198
L-reactor. Toluene (10 L) was also transferred to make sure that no
reaction-mixture was left in the hoses used for the transfer. The
mixture was then heated to 70.degree. C. before the mechanical
stirrer was turned off. The phases were allowed to separate for 30
minutes before the water phase (25 L) was discharged. The mixture
was heated to reflux and toluene (10 L) was distilled off. Water
(100 L) was added the mixture was heated to reflux again and 60 L
of water was distilled off. The remaining solution was then cooled
to RT. The title compound was never isolated; it was directly used
in the next step (Example 3C). IP sample (HPLC) of the toluene
mixture confirmed the retention time for the desired product
(t.sub.ret=2.2 minutes).
[0118] The preparation of the title compound has not been described
in D1.
Example 3A
Preparation of
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
L-malate Salt
[0119] To a 120 L receiver was added
(2R)-methyl-1-{3-[2(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine
from Example 2A (4.09 kg) and MeOH (12.7 kg) with stirring for
about 7 min until all substance had dissolved. The solution was
transferred to the 120 L reactor through an in-line filter followed
by a MeOH (2 kg) rinse. The L-malic acid (1.79 kg) was added to the
120 L receiver followed by acetone (8.8 kg) with stirring for about
13 mm until all the L-malic acid had dissolved. The solution was
transferred to the 120 L reactor through an in-line filter followed
by an acetone (2 kg) rinse. The solution in the 120 L reactor was
cooled to 5.degree. C. MtBE (25 kg) was added to the 120 L receiver
and slowly transferred through an in-line filter into the 120 L
reactor. The solution was stirred at 0.degree. C. for 1 h and
filtered onto the 18'' nutsche sending the filtrate into the 120 L
receiver. (Inspection showed little product in the nutsche; only
small amounts of oil were present.) MeOH (40 L) was added to the
18'' nutsche to dissolve the oil. The MeOH solution and the
filtrate in 120 L receiver were transferred through an in-line
filter into 120 L reactor and the solution was distilled to a solid
sending the distillate to the 120 L receiver, which was disposed,
MeOH (15 kg) was added through an in-line filter to 120 L reactor.
The solution in 120 L reactor was distilled atmospherically
replacing the MeOH with ErOH (35 kg) to a volume of 15 L. The
solution was cooled to 58.6.degree. C., seeded with EtOH (35 kg) to
a volume of 15 L. The solution was cooled to 58.6.degree. C.,
seeded with 10 g of
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazin-
e, L-malate salt, and cooling continued to 25.degree. C. Stirring
was continued for 24 h, and the resulting slurry was filtered onto
the 18'' nutsche sending the filtrate into the 120 L receiver. The
filter cake on the 18'' nutsche was rinsed with filtered EtOH (15
kg) sending the rinse into the 120 L receiver. The title compound
was dried under vacuum using 60.degree. C. nitrogen,
deagglomerated, and packaged to yield 3.58 kg (61%) of the title
compound of 98.61% GC purity.
[0120] The preparation of the title compound has not been described
in D1.
[0121] M.Pt. 124.5-126.6.degree. C.
[0122] .sup.1H NMR (400 MHz, d.sub.4-MeOH): .delta. 8.28 (1H, d,
J=2.6 Hz), 8.16 (1H, d, J=4.6 Hz), 7.78 (1H, d, J=2.5 Hz), 7.65
(1H, d, J=3.0 Hz), 7.49 (1H, dd, J=8.6, 2.5 Hz), 7.38 (1H, dd,
J=8.3, 4.8 Hz), 4.78-4.73 (2H, m), 4.65 (1H, quintet, J=3.4 Hz),
4.48 (2H, t, J=4.4 Hz), 4.29 (1H, dd, J=7.3, 5.3 Hz), 3.98 (1H, dt,
J=14.3, 3.1 Hz), 3.50 (1H, ddd, J=14.3, 11.2, 2.6 Hz), 3.31
(d.sub.4-MeOH), 3.30-3.24 (2H, m), 3.21-3.15 (2H, m), 2.77 (1H, dd,
J=15.8, 5.1 Hz), 2.53 (1H, dd, J=15.8, 7.1 Hz), 1.28 (3H, d, J=7.1
Hz, 0.00 (TMS, reference).
[0123] .sup.13C NMR (100 MHz, d.sub.4-MeOH): .delta. 179.64 (s),
176.38 (s), 157.02 (s), 152.32 (s), 147.25 (s), 142.72 (d), 138.58
(d), 135.14 (d), 133.35 (d), 125.97 (d), 123.40 (d), 69.67 (d),
68.00 (t), 65.78 (t), 48.61 (d), 48.32 (t), 44.31 (t), 41.84 (t),
40.20 (t), 14.80 (q), 0.00 (TMS, reference).
[0124] IR (diffuse reflectance) 3030 (s), 3009, 2970, 2469, (b),
2358, 2342 (b), 2318 (b), 2303, 1571 (s), 1471, 1449, 1408, 1275
(s), 1233 (s), 1206 (s), cm.sup.-1.
[0125] HRMS (FAB) calcd for C.sub.16H.sub.21N.sub.5O.sub.2 +H.sub.1
316.1773, found 316.1780.
[0126] [.alpha.].sup.25.sub.D=-21.degree. (c 0.98, water).
[0127] Anal. Calcd for
C.sub.16H.sub.21N.sub.5O.sub.2.C.sub.4H.sub.6O.sub.3; C, 53.44; H,
6.05; N, 15.58. Found: C, 53.23; H, 6.08; N, 15.29.
Example 3B
Preparation of
(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpipe-
razine, Succinate Salt
[0128]
(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyradinyl)-2-meth-
ylpiperazine (8.00 kg) obtained in Example 2B was dissolved in 24.0
kg of 1-propanol by heating to 60.5.degree. C. The undissolved
material was removed by filtration. Succinic acid (1.30 kg) was
dissolved in 23.9 kg of 1-propanol by heating to 60.6.degree. C.
All undissolved material was removed by filtration. The procedure
was repeated once with another 1.30 kg of succinic acid and 23.9 kg
of 1-propanol. All of the above solutions were mixed in a reactor.
After mixing, the content's temperature was 53.9.degree. C. The
solution was heated to 78.3.degree. C. Cooling was applied. At
40.3.degree. C., seeding with the title compound was done.
Crystallisation started after the seeding. The contents were
stirred, while the temperature was lowered to 18.3.degree. C.
during the night. The product was isolated via filtration under
suction. The resulting product cake was washed with 10 L of
1-propanol. The resulting semi-dry cake, weighing 17.2 kg was dried
at 50.degree. C./vakuum. After drying, the product, the title
compound weighed 9.16 kg (86%).
[0129] The preparation of the title compound has not been described
in D1.
[0130] Melting temperature onset, 123.degree. C.; thermal melting
range, 116-132.degree. C.
[0131] .sup.1H NMR (500 MHz, DMSO-d.sub.6): .delta. 1.12 (d, J=6.8
Hz), 1.28 (t, J=7.1 Hz), 2.34 (s), 2.79 (m), 2.79 (m), 2.95 (m),
2.95 (m), 3.20 (dddd, J=13.7, 11.5, 3.0, 1.1 Hz), 3.77 (dt, J=3.0,
13.7 Hz), 4.30 (q, J=7.1 Hz), 4.37 (strong coupled), 4.49 (dqd,
J=7.0, 6.8, 3.1 Hz), 4.62 (strong coupled), 6.89 (dd, J=5.0, 7.8
Hz), 7.33 (dd, J=1.5, 7.8 Hz), 7.58 (d, J=2.8 Hz), 7.69 (dd, J=1.5,
5.0 Hz), 7.77 (d, J=2.8 Hz).
[0132] .sup.13C-NMR (500 MHz, DMSO-d.sub.6): .delta. 14.2, 14.5,
30.5, 40.5, 44.0, 47.9, 48.4, 61.0, 64.0, 66.5, 116.8, 119.9,
130.3, 133.7, 137.2, 142.7, 146.3, 149.9, 153.8, 174.5.
[0133] Anal. Calcd for
C.sub.18H.sub.25N.sub.5O.sub.3.C.sub.4H.sub.6O.sub.4: C, 55.34%; H,
6.54%; N, 14.67%. Found: C, 54.86; H, 6.75%; N, 13.85%.
Example 3C
Preparation of
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyradinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, Phosporic Acid Salt
[0134]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2--
pyrazinyl]-2-methylpiperazine (Example 2C) in water solution was
added to the 198 L-glasslined reactor and heated to reflux. Water
(30 L) was removed by distillation. The mixture was cooled to RT.
before active charcoal (403.5 g) was added. The mixture was stirred
for 30 minutes before transferred to the 100 L glass-lined reactor
using Teflon hose and a GAF-filter (containing a polypropylene
filter bag) and a Millipore filter (containing a polvguard filler
cartridge). The hoses and filters were rinsed with water (10 L). To
the water solution in the 100 L reactor phosphoric acid (3.83 kg)
was added. The mixture was heated to reflux and water was distilled
off until an 18 L solution of
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine in water/phosphoric acid remained. Ethanol
(71 L) was added to the solution while heating the mixture to
reflux. All
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine was in solution before the heat was turned
off and the mixture allowed to cool to RT. A small amount of the
solution was taken out to create seeds and the reaction-mixture was
seeded when the temperature was 60-68.degree. C. The mixture was
allowed to crystallize for 3 days (over a weekend, no cooling media
was used) and the crystals were collected by filtration using a
Teflon filter nutch. The crystals were then dried in a vacuum oven
for 2 days at 60.degree. C. and at 100-200 mbar, 4.5 kg of the
title compound was isolated. IP sample (HPLC) of the title compound
confirmed the retention time for the title compound (t.sub.ret=2.2
minutes). The yield of the title oomponnd was 57% starting from
2-(2-dimethylaminoethoxy)pyridin-3-ol.
[0135] By starting from
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine (Example 2C) with a purity of 60-70%, the
title compound was obtained with a purity of 99% in one
crystallization step.
[0136] The preparation of the title compound has not been described
in D1.
[0137] Melting temperature onset, 148.0.degree. C. (extrapolated);
thermal melting range, 140-168.degree. C.
[0138] .sup.1H NMR (500 MHz, DMSO-d.sub.6): .delta. 1.21 (d,
J=7.0), 2.60 (s), 2.92 (td, J=12.2, 3.2 Hz), 3.02 (dd, J=13.0, 2.6
Hz), 3.08 (dd, J=13.0, 4.2 Hz), 3.16 (m), 3.17 (t, J=5.7 Hz), 3.38
(ddd, J=14.2, 11.6, 2.8 Hz), 3.94 (dt, J=14.2, 3.2 Hz), 4.40 (m),
4.52 (m), 4.59 (m), 4.61 (m), 4.67 (ddd, J=12.3, 5.1, 3.5 Hz), 6.96
(dd, J=7.8, 5.0 Hz), 7.39 (dd, J=7.8, 1.4 Hz), 7.62 (d, J=2.9 Hz),
7.71 (dd, J=5.0, 1.4 Hz), 7.80 (d, J=2.9 Hz).
[0139] .sup.--C-NMR (400 MHz, DMSO-d.sub.6): .delta. 14.3, 38,6,
42.2, 43.4, 46.2, 46.7, 55.5, 61.3, 64.0, 66.4, 117.7, 120.0,
130.9, 133.8, 137.0, 142.7, 145.7, 150.0, 152.8.
[0140] HRMS m/z calcd for C.sub.20H.sub.30N.sub.6O.sub.3
(M).sup.+402.2379, found 402.2366.
[0141] Anal. Calcd for
C.sub.20H.sub.30N.sub.6O.sub.3.3H.sub.3PO.sub.4: C; 34.49%; H,
5.64%; N, 12.07%; O, 34.46%; P, 13.34%, Found; C, 37.20%; H, 6.0%;
N, 12.5%; O, 32.4%; P, 12.1%.
Example 4
Preparation of (R)-2-methylpiperazine, L-tartrate
[0142] To the 1200 L reactor was added 60.degree. C. racemic
2-methylpiperazine (100 kg) from a drum. H.sub.2O (240 L) was
added, and the solution was cooled to 13.degree. C. To the 1200 L
receiver was added L-tartaric acid (150 kg). H.sub.2O (140 L) was
added, and the slurry was stirred for 1 h 35 mm until dissolution
of the solids was complete. The L-tartaric acid solution was
transferred to the 1200 L reactor over 2 h white maintaining a
temperature of 10-22.degree. C. in the 1200 L reactor followed by a
H.sub.2O rinse (20 L). Ethanol (163 kg) was added to the 1200 L
reactor, and the solution was cooled to 2.degree. C. The resulting
slurry was stirred tor 2 h at 2.degree. C., and filtered through a
36'' Nutsche filter sending the filtrate into the 1200 L receiver.
The 1200 L reactor and 36'' Nutsche filter were washed with
H.sub.2O (200 L), and the solids were dried to yield 214 kg oT 12%
ee (171% based on the title compound). These solids were recharged
to a clean 1200 L receiver and H.sub.2O (630 L) was added to the
1200 L receiver, which was heated to 85.degree. C. until all the
solids had dissolved. The solution was filtered through an in-line
filter (C) into the 1200 L reactor, cooled to 5.degree. C., and
stirred for 2 h. The resulting slurry was filtered through a clean
36'' Nutsche filter sending the filtrate into the 1200 L receiver.
The 1200 L reactor and 36'' Nutsche filter were washed with
H.sub.2O (200 L), and the solids were dried to yield 104 kg of 93%
ee (83% based on the title compound). These solids were recharged
to a clean 1200 L receiver and H.sub.2O (254 L) was added to the
1200 L receiver, which was heated to 85.degree. C. until all the
solids had dissolved. The solution was filtered, through an in-line
filter (C) into the 1200 L reactor, cooled to 5.degree. C., and
stirred for 2 h. The resulting slurry was filtered through a clean
36'' Nutsche filter sending the filtrate into the 1200 L receiver.
The 1200 L reactor and 36'' Nutsche filter were washed with
H.sub.2O (200 L), and the solids were dried to yield 92 kg of 99%
ee (74% based on the title compound).
[0143] D1 does not describe the preparation of the title compannd
but makes reference to J. Med. Chem. 1990, 33, 1645-1656 (D2). The
yield of the title compound according to D2, starting from racemic
2-methylpiperazine was 35%.
[0144] M.Pt. 255.0-257.0.degree. C.
[0145] .sup.1H NMR (400 MHz, D.sub.2O): .delta. 4.79 (D.sub.2O,
reference), 4.36 (2H, s), 3.73-3.64 (4H, m), 3.43 (1H, td J=13.7,
3.0 Hz), 3.34 (1H, td, J=12,7, 3.1 Hz), 3.17 (1H, dd, J=14.2, 12.8
Hz), 1.41 (3H, d, J=6.1 Hz), 0.00 (TMS, reference).
[0146] .sup.13C NMR (100 MHz, D.sub.2O: .delta. 178.46 (s), 73.91
(d), 49.02 (d), 49.00 (MeOH, reference), 45.82 (t), 40.56 (t),
40.10 (t), 15.42 (q).
[0147] IR (diffuse reflectance) 3426 (s), 3011 (s), 2999 (s), 2888
(s), 2785 (s,b), 2740 (s,b), 2703 (s,b), 2649 (s,b), 2483 (s,b),
2361 (s), 2354, 2340, 2248, 1638 (s), cm.sup.-1.
[0148] HRMS (FAB) calcd for C.sub.5H.sub.12N.sub.2 +H.sub.1
101.1079, found 101.1080.
[0149] [.alpha.].sup.25.sub.D=24.degree. (c 1.00, water).
[0150] Anal. Calcd for
C.sub.4H.sub.6O.sub.6.C.sub.5H.sub.12N.sub.2: C, 43.20; H, 7.25; N,
11.19. Found; C, 41.25; H, 7.45; N, 10.71.
Example 5
Preparation of (R)-2-methylpiperazine
[0151] (R)-2-methylpiperazine, L-tartrate from Example 4 in
H.sub.2O (182 L), and Branched octanes (200 L) were added to a 4000
L reactor and stirred until dissolved. More branched octanes (530
L) were added to the 4000 L reactor followed by 50% NaOH (1120 kg)
at a temperature between 35.degree. C. and 52.degree. C. The
solution was heated to 80.degree. C. and stirred for 2 h. The
solution was settled and the lower aqueous phase was transferred to
the 4000 L receiver. The solution in the 4000 L reactor was cooled
to -21.degree. C. and filtered onto a 48'' Nutsche filter sending
the filtrate to a 1200 L reactor. The 4000 L reactor and 48''
Nutsche filter were rinsed with branched octanes (300 L). The
solids were dried with 25.degree. C. nitrogen and collected to
yield 24.9 kg (67%) of the title compound of NLT 99% ee as
determined by chiral HPLC assay. The aqueous solution is the 4000 L
receiver was adjusted to pH 8.4 with acetic acid (812 kg) before
disposal.
[0152] The yield of the title compound according to D2, starting
from (R)-2-methylpiperazine, L-tartrate was 42%.
[0153] M.Pt. 91-93.degree. C.
[0154] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 2.97-2.68 (6H,
m), 2.35 (1H, dd, J=11.7, 10.2 Hz), 1.61 (2H, s), 1.00 (3M, d,
J=6.7 Hz), 0.00 (TMS, reference).
[0155] hu 13C NMR (400 MHz, CDCl3): .delta. 54.14 (t), 51.89 (d),
47.43 (t), 46.46 (t), 20.08 (q), 0.00 (TMS, reference). IR (mull)
3220 (s,b), 2819 (s) 2748, 2042 (w), 1995 (w), 1981 (w), 1328,
1279, 1137, 1094, 960, 859 (s), 845 (s), 795 (s), 621 (s),
cm.sup.-1.
[0156] HRMS (FAB) calcd for C.sub.5H.sub.12N.sub.2 +H.sub.1
101.1079, found 101.1080.
[0157] [.alpha.].sup.25.sub.D=-17.degree. (c 0.85,
CH.sub.2Cl.sub.2).
[0158] Anal. Calcd for C.sub.5H.sub.12N.sub.2: C, 59.96; H, 12.07;
N, 27.97. Found: C, 59.25; H 11.71; N, 27.64.
Example 6
Preparation of (R)-3-methyl-1-tritylpiperazine
[0159] To the 1200 L realtor was dissolved (R)-2-methylpiperazine
from Example 5 (25 kg) in CH.sub.3CN (319 kg) at 15.degree. C. to
25.degree. C. until dissolution was complete (10 min.) After
cooling to 5.degree. C. to 10.degree. C. Et.sub.3N (63 kg) was
added. To the 1200 L receiver trityl chloride (69.5 kg) was
dissolved in CH.sub.2Cl.sub.2 (106 kg) at 15.degree. C. to
25.degree. C. The solution in the receiver was transferred to the
reactor over 0.5 h with a CH.sub.2Cl.sub.2 rinse (27 kg), and the
solution was heated to 20.degree. C. to 30.degree. C. The reaction
was monitored by GLC and was complete in 1 h. The resulting slurry
was cooled to 8.degree. C. to 12.degree. C.; filtered onto a 48''
Nutsche filter, and rinsed with CH.sub.3CN (40 kg at 8.degree. C.
to 12.degree. C.). The filter cake was dried using 50.degree. C. to
55.degree. C. nitrogen to afford 25.26 kg of the by-product
Et.sub.3NHCl (74% yield; easy to filter off the by-product). The
filtrate was transferred to the 1200 L reactor and cooled further
to -8.degree. C. to -10.degree. C. for 1 h. The resulting slurry
was filtered onto a 24'' Nutsche filter and rinsed with -8.degree.
C. to -10.degree. C. CH.sub.3N (24 kg) sending the filtrate and
rinse to the 1200 L receiver. The filter cake was dried with
50.degree. C. to 55.degree. C. nitrogen to afford another 2.98 kg
Et.sub.3NHCl (9% yield). The filtate was transferred to the 1200 L
reactor with a CH.sub.3CN (10 kg) rinse, and distilled under vacuum
to an oil of the title compound of 97.99% GC purity. The yield was
quantitative.
[0160] M.Pt. 134-136.degree. C.
[0161] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.55-7.40 (6H, br
s), 7.25 (6H, t, J=7.9 Hz), 7.14 (3H, t, J=7.1 Hz), 3.21-3.13 (2H,
m), 3.10-2.90 (1H, br s), 2.94 (2H, t, J=13.0 Hz), 1.60 (1H, br s),
1.48 (1H, br s), 1.15 (1H, br s), 0.94 (3H, d, J=6.1 Hz), 0.00
(TMS, reference).
[0162] .sup.13C NMR (100 MHz, CDCl.sub.3): .delta. 129.41 (d),
127.46 (d), 125.96 (d), 125.83 (s), 56.12 (t), 51.23 (d), 48.73
(t), 46.45 (t), 20.05 (q), 0.00 (TMS, reference).
[0163] IR (diffuse reflectance) 2964, 2835, 2483 (w), 2350 (w),
2339 (w), 1956 (w), 1490, 1025, 909, 742 (s), 717, 710 (s), 703
(s), 697 (s), 629, cm.sup.-1.
[0164] HRMS (EI) calcd for C.sub.24H.sub.26N.sub.2 342.2096, found
342.2101.
[0165] [.alpha.].sup.25.sub.D=-12.degree. (c 1.00,
CH.sub.2Cl.sub.2).
[0166] Anal. Calcd for C.sub.24H.sub.26N.sub.2: C, 84.17; H, 7.65;
N, 8.18. Found: C, 84.12; H, 7.64; N, 7.94.
Example 7
Preparation of
(2R)-1-(3-chloro-2-pyrazinyl)-2-methyl-4-tritylpiperazine
[0167] The product from Example 6 was dissolved in DMF (150 kg) at
25.degree. C. The solution in the 1200 L reactor was cooled to
2.degree. C. and 25.degree. C. and transferred into the 1200 L
receiver with a DMF rinse (30 kg). Anhydrous K.sub.2CO.sub.3 (103
kg) was added to the 1200 L reactor. The solution in the 1200 L
receiver was transferred to the 1200 L reactor with a DMF rinse (30
kg). The 2,3- dichloropyrazine (48.5 kg) was added with a DMF rinse
(4 L). The 1200 L reactor was heated to reflux at 127.degree. C. to
133.degree. C. Samples were taken every 12-18 h and monitored by
GC. The reaction was complete in 41.5 h. The contents of the 1200 L
reactor were cooled to 35.degree. C. to 45.degree. C. and
transferred onto a 48'' Nutsche filter sending the filtrate sent to
the 1200 L receiver. MtBE rinses (2.times.200 kg at 35.degree. C.
to 45.degree. C.) of the 1200 L reactor were transferred onto the
48'' Nutsche filter sending the rinses to the 1200 L receiver. The
filtrate in the 1200 L receiver was transferred to the 1200 L
reactor with a MtBE rinse (50 kg). The solution in the 1200 L
reactor was concentrated under vacuum to remove MtBE and DMF.
MgSO.sub.4 was added to a 48'' Nutsche (181 kg) and the 1200 L
receiver (45 kg). MtBE (625 kg) was added to the 1200 L reactor,
heated to 40.degree. C. to 45.degree. C., and stirred to dissolve
the title compound. The solution was cooled to 15.degree. C. to
30.degree. C. and transferred into the 1200 L receiver with a MtBE
rinse (100 kg). The slurry in the 1200 L receiver was stirred for
3.5 h and filtered onto the 48'' Nutsche filter sending the
filtrate into the 1200 L reactor. The 1200 L receiver was rinsed
with MtBE (2.times.250 kg at 15.degree. C. to 30.degree. C.) and
transferred to the 48'' Nutsche filter sending the rinses into the
1200 L reactor. The filtrate in the 1200 L reactor was distilled
under vacuum to afford the title compound of 87.83% GC parity. The
yield was quantitative.
[0168] .sup.1H NMR (400 MHz, d.sub.6-DMSO at 87.degree. C.):
.delta. 8.18 (1H, d, J=2.5 Hz), 7.89 (1H, d, J=2.1 Hz), 7.47 (6H,
d, J=7.6 Hz), 7.31 (6H, 5, J=7.6 Hz), 7.18 (3H, t, J=7.4 Hz),
4.31-4.26 (1H, m), 3.66 (1H, ddd, J=12.4, 9.9, 2.5 Hz), 3.48 (1H,
br d, J=12.7 Hz), 2.72 (1H, br d, J=11.2 Hz), 2.59 (1H, br d,
J=10.7 Hz), 2.49 (d.sub.6-DMSO, reference), 2.14 (1H, br dd,
J=11.2, 2.0 Hz), 1.89 (1H, br t, J=9.9 Hz), 1.37 (3H, d, J=6.6
Hz).
[0169] .sup.13C NMR (100 MHz, d.sub.6-DMSO at 87.degree. C.):
.delta. 153.85 (s), 141.51 (s), 139.79 (d), 134.86 (d), 128.57 (d),
127.02 (d), 135.60 (d), 76.07 (s), 52.09 (t), 50.84 (d), 47.68 (t),
44.40 (t), 39.52 (d.sub.6-DMSO, reference), 15.39 (q).
[0170] IR (diffuse reflectance) 2963 (s), 2350 (w), 2317 (w), 1959
(w), 1921 (w), 1906 (w), 1501, 1488, 1465, 1443 (s), 1411 (s), 1143
(s), 1022, 744, 708 (s), cm.sup.-1.
[0171] HRMS (FAB) calcd for C.sub.28H.sub.27ClN.sub.4 +H.sub.1
455.2002, found 455.2004.
[0172] [.alpha.].sup.25.sub.D=-36.degree. (c 0.98,
CH.sub.2Cl.sub.2).
[0173] Anal. Calcd for C.sub.28H.sub.27ClN.sub.4: C, 73.91; H,
5.98; N, 12.31; Cl, 7.79. Found: C, 74.26; H, 6.84; N, 10.74.
Example 8
Preparation of (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine
[0174] To the 1200 L reactor containing the product from Example 7
was added IPA (707 kg). Stirring at reflux (77.degree. C. to 83+
C.) was continued until dissolution was complete. The solution in
the 1200 L reactor was transferred to the 4000 L reactor with a IPA
rinse (100 kg) and heated to reflux (77.degree. C. to 83.degree.
C). A 10% sulfuric acid solution (gtiving a clean reaction) was
prepared in the 4000 L receiver by adding water (245 L) and 98%
H.sub.2SO.sub.4 (27 kg). The H.sub.2SO.sub.4 solution was stirred
for 10 minutes at 20.degree. C. to 60.degree. C. and transferred to
the 4000 L reactor while maintaining the 4000 L reactor temperature
between 60.degree. C. to 85.degree. C. The 4000 L receiver was
rinsed with water (25 L) sending the rinse to the 4000 L reactor.
The 4000 L reactor was heated to reflux (77.degree. C. to
82.degree. C.). The reaction was monitored by GC and was complete
in 30 min. The contents in the 4000 L reactor were cooled to
35.degree. C. to 40.degree. C. The IPA was removed under vacuum
distillation. Water (1265 L) and MtBE (511 kg) was added to the
4000 L reactor. After stirring and settling, the aqueous layer was
transferred into the 4000 L receiver. The MtBE layer in the 4000 L
reactor was disposed. MtBE (511 kg) was added to the 4000 L
receiver, the solution was stirred and settled for at least 15 min.
The aqueous layer was transferred to the 4000 L reactor. The MtBE
layer in the 4000 L receiver was disposed. The pH was adjusted to
9.5 to 10.5 using 47% K.sub.2CO.sub.3 (206 kg) with a water rinse
(50 L) of the add line. CH.sub.2Cl.sub.2 (2.times.765 L,
1.times.255 L) was used to extract the title compound from the 4000
L reactor sending the CH.sub.2Cl.sub.2 extractions into the 4000 L
receiver. The organic solution in the 4000 L receiver was
transferred to the 4000 L reactor with a CH.sub.2Cl.sub.2 rinse
(100 L). The CH.sub.2Cl.sub.2 was removed by distillation. Toluene
(1000 L) was added to the 4000 L reactor and subsequently removed
by vacuum distillation to afford a toluene solution of the title
compound of 95.77% GC purity. The yield was quantitative.
[0175] Summarizing the steps of Examples 5-8, the yield of the
product from Example 8 was 67% starting from
(R)-2-methylpiperazine, L-tartrate. According to D1, the yield of
the same product was 60% starting from (R)-2-methylpiperazine,
L-tartrate. The step described in D1 corresponding to the process
in Example 8 was performed in a mixture of hot ethanol and 10%
aqueous hydrochloric acid.
[0176] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.12 (1H, d,
J=2.6 Hz), 7.87 (1H, d, J=2.6 Hz), 4.18-4.12 (1H, m), 3.39 (2H, t,
J=3.6 Hz), 3.12 (1H, dd, J=12.2, 3.6 Hz), 3.06 (1H, dt, J=12.2, 3.6
Hz), 3.02-2.95 (1H, m), 2.81 (1H, dd, J=12.2, 4.0 Hz), 1.90 (1H, br
s), 1.21 (3H, d, J=6.6 Hz), 0.00 (TMS, reference).
[0177] .sup.13C NMR (100 MHz, CDCl.sub.3): .delta. 155.15 (s),
140.85 (s), 139.93 (d), 135.15 (d), 51.06 (d), 50.98 (t), 45.94
(t), 45.10 (t), 14.72 (q), 0.00 (TMS, reference).
[0178] IR (liq.) 2940, 2389 (w), 2149 (w), 1996 (w), 1556 (s), 1504
(s), 1459 (s), 1440 (s), 1415 (s), 1367, 1330 (s), 1132 (s), 1107
(s), 1100 (s), 1049 (s), cm.sup.-1.
[0179] [.alpha.].sup.25.sub.D=-43.degree. (c, 0.59,
CH.sub.2Cl.sub.2).
[0180] HRMS (FAB) calcd for C.sub.9H.sub.13ClN.sub.4 +H.sub.1
213.0907, found 213.0909.
[0181] Anal. Calcd for C.sub.9H.sub.13ClN.sub.4; C, 50.83; H, 6.16;
N, 26.34. Found: C, 50.48; H, 6.19; N, 26.47.
Example 9
Preparation of (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine,
hydrochloride
[0182] To a 200 L reactor was added the product from Example 8 in
toluene solution (ca 25 kg thereof in 93 kg solution) with an EtOAc
rinse (10 kg). Solvent was removed using vacuum until a volume of
35 L was reached. To remove most of the toluene, EtOAc (2.times.90
kg) was added to the 200 L reactor and distilled until a volume of
35 L was reached. EtOAc (90 kg) was added to the 200 L reactor and
heated to reflux (78.degree. C.). The slurry in the 200 L reactor
was cooled to 55.degree. C. to 60.degree. C. filtered through a bag
filter to remove solid impurities sending the filtrate to the 200 L
receiver. The 200 L reactor was rinsed with EtOAc (5 kg) sending
the rinse into the 200 L receiver. The solution in the 200 L
receiver was transferred to the 400 L reactor with an EtOAc rinse
(5 kg). 37% HCl (9.0 kg) was added to the 200 L receiver and rinsed
with EtOAc (9 kg). The 37% HCl solution was transferred to the 200
L reactor while maintaining a temperature of 73.degree. C. to
80.degree. C. in the 200 L reactor. The solution in the 200 L
reactor was maintained at 72.degree. C.C for 10 min. The solution
was cooled to -25.degree. C. to -30.degree. C. for 2 h 45 min. The
resulting slurry in the 200 L reactor was filtered onto an 18''
Nutsche filter sending the filtrate into the 200 L receiver. The
reactor and nutsche were rinsed with -25.degree. C. EtOAc
(3.times.45 kg) sending the filtrate into drums. The filter cake
was dried to afford 24.5 kg (79%) of the title compound of 98.4% GC
purity. A 2.sup.nd similar run gave 23.1 kg for a total of 47.6 kg
(77%).
[0183] M.Pt. 209.0-210.5.degree. C.
[0184] .sup.1H NMR (400 MHz, d.sub.4-MeOH): .delta. 8.29 (1H, d,
J=2.6 Hz), 8.07 (1H, d, J=2.6 Hz), 4.83 (2H, br s), 4.30 (1H,
sexlet, J=5.8 Hz), 3.68-3.56 (2H, m), 3.40 (1H, dd, J=14.2, 4.7
Hz), 3.37 (1H, m), 3.31 (1H, br s), 3.23 (1H, dd, J=12.7, 5.1 Hz),
1.30 (3H, d, J=6.6 Hz), 0.00 (TMS, reference).
[0185] .sup.13C NMR (100 MHz, d.sub.4-MeOH): .delta. 155.45 (s),
143.28 (s), 141.90 (d), 138.91 (d), 50.32 (d), 48.60 (t), 44.26
(t), 43.31 (t), 15.41 (q), 0.00 (TMS, reference).
[0186] IR (diffuse reflectance) 2934, 2802, 2781 (s), 2744 (s),
2717, 2684, 2470, 2425, 2351 (w), 2335 (w), 2269 (w), 1453 (s),
1412 (s), 1148 (s), 881 cm.sup.-1.
[0187] HRMS (FAB) calcd for C.sub.9H.sub.13ClN.sub.4 +H.sub.1
213.0907, found 213.0912.
[0188] [.alpha.].sup.25 .sub.D=-24.degree. (c 0.92, water).
[0189] Anal. Calcd for C.sub.9H.sub.13ClN.sub.4HCl: C, 43.39; H,
5.66; N, 22.49. Found: C, 43.38; H, 5.75; N, 22.37.
Example 10
Preparation of
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxyl]-2-pyrazinyl}piperazine,
fumarate
[0190] To a 400 L reactor was added a solution of the product from
Example 2A in MeOH (ca. 12.4 kg in 90 L solution) followed by a
MeOH rinse (5 kg). The solution was distilled to a volume of 50 L.
The fumaric acid (4.6 kg) was added to the 400 L reactor using an
addition funnel. The slurry was stirred for 45 min at 25.degree. C.
to 30.degree. C. until all the solids dissolved. MtBE (133 kg) was
slowly added, the resulting slurry was cooled to 30.degree. C., and
the solids were filtered onto an 18'' Nutsche sending the filtrate
into the 400 L receiver. The 400 L reactor and 18'' Nutsche were
rinsed with MtBE (16 kg) sendin the rinse into the 400 L receiver.
The title compound was dried and packaged to yield 123 kg (58%) of
97.4% GC purity. The product purity can be slightly improved by
repeating the crystallization.
[0191] M.Pt. 125.5-126.5.degree. C.
[0192] .sup.1H NMR (400 MHz, d.sub.4-MeOH): .delta. 8.27 (1H, d,
J=3.1 Hz), 8.15 (1H, d, J=4.5 Hz), 7.78 (1H, d, J=2.6 Hz), 7.65
(1H, d, J=23.1 Hz), 7.48 (1H, dd, J=8.1, 2.5 Hz), 7.38 (1H, dd,
J=8.5, 4.9 Hz), 6.69 (2H, s), 4.36 (4H, br s), 4.74 (2H, q, J=4.6
Hz), 4.69-4.63 (1H, m), 4.48 (1H, t, J=4.3 Hz), 3.99 (1H, dt,
J=11.7, 3.1 Hz), 3.51 (1H, ddd, J=14.7, 11.2, 3.0 Hz), 3.30-3.26
(2H, m), 3.22-3.15 (2H, m), 1.28 (3H, d, J=6.7 Hz), 0.00 (TMS,
reference).
[0193] .sup.13C NMR (100 MHz, d.sub.4-MeOH): .delta. 171.20 9s),
156.98 (s), 152.27 (s), 147.16 (s), 142.67 (d), 138.51 (d), 136.14
(d), 135.11 (d), 133.33 (d), 125.94 (d), 67.97 (t), 65.75 (t),
48.16 (t), 48.54 (d), 44.71 (t), 40.07 (t), 14.79 (q), 0.00 (TMS,
reference).
[0194] IR (diffuse reflectance) 3047 (s), 3028 (s,b), 2985 (s,b),
2976 (s), 2962 (s), 2350 (w), 2339 (w), 2318 (w), 2063 (w), 1990
(w), 1710 (s), 1442 (s), 1261 (s), 1206 (s), 1190 (s),
cm.sup.-1.
[0195] [.alpha.].sup.25.sub.D=-20.degree. (c 0.98, water).
[0196] Anal. Calcd for
C.sub.16H.sub.21N.sub.5O.sub.2.C.sub.4H.sub.4O.sub.4: C, 55.68; H,
5.84; N, 16.23. Found: C, 55.01; H, 5.88; N, 15.65.
Example 11
Comparison of the Properties of Different Salts of Example 2A
[0197] The following salts were prepared by Chemical development,
Stockholm and Kalamazoo and evaluated by Pharmaceutical
Development, Nerviano: [0198]
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine
(free base; see Example 2A) [0199]
(2R)-methyl-1-{3-[2-(3-pyradinyloxy)ethoxy]-2-pyrazinyl}piperazine,
L-malate (see Example 3A) [0200]
(2R)-methyl-1-{3-[2-(3-pyradinyloxy)ethoxy]-2-pyrazinyl}piperazine,
fumarate (see Example 10) [0201]
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
hydrochloride (see D1, Example 173) [0202]
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
acetate [0203]
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
benzoate [0204]
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
cinnamate.
[0205] Positive data for most salts, except for the free-base and
the hydrochloride. NMR analysis was positive for the free-base. The
hydrochloride showed problems related to the stoichiometric
ratio.
Crystallinity (X-rays)
[0206] Positive results for free base, acetate, benzoate, L-malate,
and cinnamate were obtained. Most samples were substantially
crystalline. Hydrochloride and especially fumarate came out to be
of lower crystallinity.
Hygroscopicity (DVS, Storage at RT/Different RHs and at 40.degree.
C./75% RH)
[0207] Positive results were obtained on benzoate, L-malate, and
cinnamate. They showed lower hydroscopicity (.ltoreq.5%)
equilibrium moisture contents at RT/90%RH). Moisture-related
effects on the bulk solid state properties of the benzoate salt
were observed (cake formation and darkening) but without changes on
the DSC pattern. Acetate and hydrochloride were deliquescent (the
former at RT/75% RH while the latter at higher values). Fumarate
was subjected to hydrate conversion upon exposition at RT/90% RH.
Exposition to 40.degree. C./75% RH showed good behavior of
cinnamate and L-malate, recovered as powders showing substantially
unchanged properties.
Solubility (Water, pH 1.2 and pH 7.4 Buffers)
[0208] Positive results were obtained for all salts (.apprxeq.300
mg/ml FBE) with the exception of cinnamate whose solubility in
water is about 8-10 mg/ml FBE.
Intrinsic Dissolution Rate (pH 1.2)
[0209] All results confirmed the solubility data. IDRs were about
10.sup.-1 mgsec.sup.-1cm.sup.-2 while cinnamate had much lower
dissolution rate (10.sup.-3 that means -2 order of magitude lower
than the others). Acetate salt showed problem during tablet
preparation (sticking to the punch).
Chemical Stability (2 Weeks at 65.degree. C.)
[0210] Positive data for benzoate, L-malate, and cinnamate were
obtained. Fumarate and acetate seemed to be the less stable salts
either at RT/99% RH and at high temperature. Formation of the
reaction prodnct with fumaric acid was also observed. These samples
showed unchanged DSC patterns except for the acetate (peak
broadening).
Polymorphism
[0211] The tested conditions (RT evaporation, cooling
crystallisation at -20.degree. C. in different solvent or mixtures)
did not show other polymorphs of benzoate and L-malate salts.
Manufacturing Method
[0212] Benzoate, L-malate, and cinnamate seemed to be easier to
crystallize than fumarate, hydrochloride and free base.
Toxicological Acceptability
[0213] There are few marketed drugs that are cinnamate salts and no
much information in literature. Oral LD.sub.50s in rats are about
2500 mg/kg and 5 g/kg in mice.
[0214] Malic acid is an intermediate in the citric acid cycle and
occurs naturally in apple and many fruits. It is FDA approved as
food additive. A lot of drugs are approved in Europe and US as
malate salts.
[0215] In summary, of the salts examined above,
(2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine,
L-malate seems to be the best choice of the salts examined due to
its high crystallinity, low hygroscopicity, high chemical stability
and low toxicity.
Example 12
Comparison of the Properties of Different Salts of Example 2B
[0216] The following salts have been prepared: [0217]
(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpipe-
razine (free base, see Example 2B) [0218]
(2R)-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpipe-
razine, acetate [0219]
(2R-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpiper-
azine, fumarate (see D1, Example 200) [0220]
(2R-1-(3-{2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy}-2-pyrazinyl)-2-methylpiper-
azine, succinate (see Example 3B).
Crystallinity (Powder X-ray Diffraction)
[0221] For the succinate salt, the degree of crystallinity was very
high. The degree of crystallinity decreased in the order
succinate>acetate>fumarate.
Thermal Properties
[0222] For the free base and the acetate salt the melting
temperature onset was low (81.degree. C. and 96.degree. C.,
respectively). These low melting points can be drawbacks in future
development work. For the succinate and fumarate salts the thermal
properties were fair since the extrapolated melting temperature
onset was 123.degree. C. and 149.degree. C., respectively.
Hygroscopicity
[0223] All but the acetate salt had acceptable properties with
respect to hygroscopicity. The acetate salt was very hygroscopic
and showed a pronounced hysteresis at high values of relative
humidity.
[0224] Solubility and Intrisic Dissolution Rate
[0225] The solubility of the succinate salt, in all investigate
media, was at least 250 mg/ml. For the fumarate salt the solubility
was >93 mg/ml in 0.9% w/w NaCl and >68 mg/ml in phosphate
buffer at pH 7.4. Hence, the solubility of succinate was in all
instances higher than the fumarate salt.
[0226] The intrinsic dissolution rate studies indicated the
dissolution rate to increase according to the order
base<fumarate<succinate.
[0227] In conclusion, with the respect to the solubility and the
intrinsic dissolution rate, the succinate salt proved to have the
most favourable qualities of the salts and the free base
studied.
Impurities
[0228] Analysis (LC-UV-MS) of the fumarate salt revealed the
presence of a fumarate adduct (.about.1%) and the formation of
diraers of the free base (0.2%). The fumarate adduct may be a
Michael adduct between the piperazine ring and fumaric acid.
Conclusion
[0229] The succinate salt hade the overall best state properties,
good crystallinity, a relatively high melting point, a high
solubility and a high intrinsic dissolution rate. The acetate salt
proved to be both hygroscopic and to have a low melting raage. The
solubility, intrinsic dissolution rate and the degree of
crystallinity of the fumarate salt was inferior to that of the
succinate salt. In view of the properties of the different salts
investigated the best candidate for further developement is the
succinate salt.
Example 13
Comparison of the Properties of Different Salts of Example 2C
[0230] The following salts have been prepared: [0231]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridimyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine (free base, see Example 2C) [0232]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, phosphoric acid salt (see Example 3C)
[0233]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, acetate [0234]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-2-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, citrate [0235]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2methylpiperazine, edeteate [0236]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, oxalate [0237]
(2R)-2-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, succinate [0238]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, D-tartrate [0239]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, 1,3,5-benzenetricarboxylate [0240]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, galactareate (mucic acid salt) [0241]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-2-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, 1,5-naphthalenedisulfonate [0242]
(2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}ethoxy)-2-pyrazi-
nyl]-2-methylpiperazine, terephthalate.
Crystallinity (Powder X-ray Diffraction)
[0243] The acetate- and the oxalate salt had a high degree of
crystallinity whilst the crystallinity of the succinate salt and
the phosphoric acid salt ranged from predominantely crystalline to
moderately crystallinity. The D-tartrate salt had a low degree of
crystallinity. Two salts, edeteate and citrate proved to be
practically amorphous. The free base is a viscous oil at ambient
conditions. The benzenetricarboxylate, naphthalenedisulfonate and
terephthalate were predominantly crystalline, whilst the
galactareate was partially amorphous.
Hygroscopicity
[0244] The acetate, citrate, edeteate, succinate and D-tartrate
salts proved to be very hygroscopic and deliquescent. Also the free
base was hygroscopic. The hygroscopicity of the the oxalate and
phosphoric acid salt was low. The hygroscopicity of the
benezenetricarboxylate, naphthalenedisulfonate and terephthalate
was low, moderate and high (deliquescent), respectively.
Solubility
[0245] The solubility of the phosphoric acid salt was, in all
investigated media, not less than 590 mg/ml. Preliminary studies
indicated the benzenetricarboxylic acid to have a solubility of
>19 mg/ml in SGF (simulated gastric ffluid without enzymes; pH
of filtrate 2.9), 11 mg/ml in SIF (simulated intestinal fluid
without enzymes; pH of filtrate 4.2) and in purified water
.apprxeq.4 mg/ml (pH of filtrate 3.6). The solubility of the
naphthalenedisulfonate was high>540 mg/ml. preliminary studies
of the solubility of the terephthalate salt in purified water
indicated the solubility to be low (<1 mg/ml).
Toxicological Acceptability
[0246] Regarding the oxalate salt although its solid state
properties are good it was deemed inappropriate due to
toxicological reasons. The benzenetricarboxylate salt had the
overall most promising solid state properties but the solubility
was lower than for the phosphoric acid salt and requires a
toxicological evaluation. The phosphoric acid salt was deemed to be
the best choice of the salts regarding high crystallinity, low
hygroscopicity, high solubility, and low toxicity.
* * * * *